Home | Sitemap | Search | ContactA- A A+
    Public Member Support us  
Home > News > Trial News

Trial News 


Clinical Trials

IBCSG 23-01 NEJM Journal Watch - Summary and Comment
Omission of Axillary Dissection for Minimal Node-Positive Breast Cancer
William J. Gradishar, MD reviewing Galimberti V et al. Lancet Oncol 2018 Sep 5  


We are glad to share the July 2018 version of the POSITIVE Progress! It contains information about the study awareness video and funding initiatives. It also has a message from North American Trial Chair, a note from Europa Donna Serbia together with insight on central trial coordination and data management, etc.
Vol1, Issue 2, August 2018

IBCSG Circular Letter  
August 2018
Volume 24 Issue 2

TEXT & SOFT Press Release ASCO 2018

Ovarian Suppression Reduces Recurrence and Can Improve Survival in Young Breast Cancer Patients




Moore HCF, Unger JM, Phillips KA, Boyle F, Hitre E, Moseley A, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens FL, Gelber RD, Hortobagyi GN, Albain KS. Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230. J Natl Cancer Inst. doi: 10.1093/jnci/djy185. 2018 Oct 27. [Epub ahead of print] (IBCSG 34-05) (Journal Impact Factor 12.589).

367. Galimberti V, Cole BF, Viale G, Veronesi P, Vicini E, Intra M, Mazzarol G, Massarut S, Zgajnar J, Taffurelli M, Littlejohn D, Knauer M, Tondini C, Di Leo A, Colleoni M, Regan MM, Coates AS, Gelber RD, Goldhirsch A. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol. doi: 10.1016/S1470-2045(18)30380-2. 2018 September 5. [Epub ahead of print] (23-01) (Journal Impact Factor 36.418).

366. Van Asten K, Slembrouck L, Olbrecht S, Jongen L, Bouckaert O, Wildiers H, Floris G, van Limbergen E, Weltens C, Smeets A, Paridaens R, Giobbie-Hurder A, Regan MM, Viale G, Thürlimann B, Vergote I, Christodoulou E, van Calster B, Neven P. Prognostic value of progresterone receptor by subtype in patients with estrogen receptor-positive, HER-2 negative breast cancer. Oncologist. doi: 10.1634/theoncologist.2018-0176. 2018 August 31. [Epub ahead of print] (BIG 1-98) (Journal Impact Factor 5.306).


The next IBCSG Annual Meeting will take place in Vienna Austria on March 23 and 24, 2019.       

16th St. Gallen International Breast Cancer Conference Primary Therapy of Early Breast Cancer

New publications are available 

All News